Bone metastases have a major impact on morbidity and on mortality in cancer patients. Despite its clinical relevance, metastasis remains the most poorly elucidated aspect of carcinogenesis. Different pathways or molecules such as RANK/RANKL/OPG, cathepsin K, endothelin-1, Wnt/DKK1 and Src have recently emerged as potential targets, and preclinical and clinical trials are now underway. The results from clinical trials indicate the importance of treating and preventing bone metastases in many different cancer populations.
Bisphosphonate anticancer activity / Tonini, G; Vincenzi, B; Santini, D. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 12:5(2011), pp. 681-683. [10.1517/14656566.2011.543279]
Bisphosphonate anticancer activity
Santini D
2011
Abstract
Bone metastases have a major impact on morbidity and on mortality in cancer patients. Despite its clinical relevance, metastasis remains the most poorly elucidated aspect of carcinogenesis. Different pathways or molecules such as RANK/RANKL/OPG, cathepsin K, endothelin-1, Wnt/DKK1 and Src have recently emerged as potential targets, and preclinical and clinical trials are now underway. The results from clinical trials indicate the importance of treating and preventing bone metastases in many different cancer populations.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
